Recent data from the Advance-HTN trial suggests that lorundrostat, a novel drug developed by Mineralys Therapeutics, significantly lowers blood pressure in patients suffering from uncontrolled and resistant hypertension. In a pivotal Phase 2 trial, lorundrostat demonstrated a remarkable average drop of 15.4 mmHg in blood pressure. Cardiologists express cautious optimism regarding its potential as a later-line treatment option for resistant hypertension. Mineralys Therapeutics plans to further discuss these findings in an upcoming conference call featuring Dr. Luke Laffin and during a webinar aimed at providing additional insights into the ongoing progress in hypertension treatment.